Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.

Anticancer research - 1 Feb 2021

Akamatsu Hiroaki, Ozawa Yuichi, Oyanagi Jun, Fujimoto Daichi, Hata Akito, Katakami Nobuyuki, Tomii Keisuke, Murakami Eriko, Sugimoto Takeya, Shimokawa Toshio, Koh Yasuhiro, Yamamoto Nobuyuki

Abstract excerpt

BACKGROUND/AIM: To explore the safety of osimertinib plus ramucirumab in patients with EGFR-mutated lung adenocarcinoma. PATIENTS AND METHODS: Six advanced lung adenocarcinoma patients with EGFR mutation were treated with osimertinib 80 mg/day plus ramucirumab 10 mg/kg, every two weeks. Defined dose-limiting toxicity (DLT) was assessed within the first two treatment cycles. RESULTS: Of those enrolled, five...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Circulating Tumor DNA

Share to Disease-Free Survival

Share to Drug Administration Schedule

Source

Identifiers

PMID: 33517297
DOI: 10.21873/anticanres.14844

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.PMID 33517297Read ↗

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study.Semantic proximity Read ↗

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.Semantic proximity Read ↗

Osimertinib plus Ramucirumab: The Best of Both Worlds?Semantic proximity Read ↗

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.Semantic proximity Read ↗

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).Semantic proximity Read ↗

Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)Semantic proximity Read ↗

Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancerSemantic proximity Read ↗

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.Semantic proximity Read ↗

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.Semantic proximity Read ↗

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.